hrp0092p2-276 | Thyroid | ESPE2019

Novel Thyroid Hormone Receptor β-Gene Mutations in Resistance to Thyroid Hormone

Kim Heung Sik , Kim Se Jin , Kim Ga Hyun , Kang Seok Jin

The syndrome of resistance to thyroid hormone (RTH) is caused by decreased tissue responsiveness to thyroid hormone. With the exception, inheritance of RTH is autosomal dominant. The receptors are encoded by two genes (THRA and THRB), each of which undergoes alternate splicing to generate receptor subtypes (TRa1, TRβ1, and TRβ2), with differing tissue distributions.Here we describe a child with novel heterozygous mutations for THRB. Nine-months-old ...

hrp0086p1-p446 | Fat Metabolism and Obesity P1 | ESPE2016

Bioinactive Leptin is not Frequently Detected in Severe Early Onset Childhood Obesity

Stanik Juraj , Kratzsch Jurgen , Scheuermann Kathrin , Gašperikova Daniela , Kiess Wieland , Korner Antje

Background: Rodent models of leptin inactivity show progressive obesity due to exaggerated food intake. In humans, only rare monogenic cases of leptin deficiency and almost absent circulating leptin levels have been identified. Recently, two cases of children with early onset massive obesity due to biofunctionally inactive leptin in the face of normal total levels have been identified.Objective and hypotheses: Here we aimed to identify leptin inactivity ...

hrp0082p2-d3-309 | Bone (2) | ESPE2014

Risedronate Use in Duchenne Muscular Dystrophy: a Pilot Randomised Control Trial

Mc Sweeney Niamh , Mc Kenna Malachi , van der Kamp Susan , Kilbane Mark , Mc Donnell Ciara , Murphy Nuala , Webb David , Lynch Bryan

Background: Boys affected with Duchenne Muscular Dystrophy (DMD) have lower bone mineral density compared with unaffected boys.Objective and hypotheses: We sought to determine the effects on bone mineral density (BMD) of 1 year treatment with Risedronate and calcium/vitamin D supplementation vs calcium/vitamin D supplementation alone.Method: BMD was measured at spine and whole body. We obtained early morning fasting blood samples f...

hrp0095p1-32 | Bone, Growth Plate and Mineral Metabolism | ESPE2022

Six-year clinical outcome of enzyme replacement therapy for patients with perinatal lethal and infantile hypophosphatasia in Korea

Yoon Cho Sung , Kim Min-Sun , Noh Eu-Seon , young Bae Ga , won Park Sung , Jin Dong-Kyu , Kim Insung

Hypophosphatasia (HPP) is a genetic skeletal disease caused by loss-of-function mutations of ALPL encoding tissue-nonspecific alkaline phosphatase (TNSALP). The clinical presentation of HPP varies greatly, ranging from stillbirth without bone mineralization to findings in later life, such as delayed walking, short stature, skeletal deformities, bone pain, and pathologic fractures. The diagnosis is based on clinical examination, radiographic findings, biochemical parameters of ...

hrp0095p1-542 | Pituitary, Neuroendocrinology and Puberty | ESPE2022

Clinical Manifestation and Treatment Outcomes of Pheochromocytoma and Paraganglioma in Children and Adolescents : A 26-year Single- Center Experience

Young Bae Ga , Kim Min-Sun , Noh Eu-Seon , won Park Sung , Yoon Cho Sung , Jin Dong-Kyu

Purpose: Pheochromocytoma (PCC) and paraganglioma (PGL) (PPGL) are rare neuroendocrine tumors, and there is little information on how to treat them in children and adolescents. The objective of this study was to demonstrate the clinical presentation and treatment outcomes in children and adolescents with PPGL in a single Korean tertiary care hospital.Methods: Korean patients diagnosed with PCC and PGL before the age of 2...

hrp0095p1-595 | Thyroid | ESPE2022

Treatment of Graves' Disease in Children and adolecents with Long-Term Antithyroid Drugs: A 20-Year Single-Center Experience

Young Bae Ga , Kim Min-Sun , Noh Eu-Seon , Won Park Sung , Yoon Cho Sung , Jin Dong-Kyu

Background/purpose: Graves’ disease (GD) is an autoimmune disorder characterized by hyperthyroidism, diffuse goiter, and/or ophthalmopathy that is caused by the activation of the thyroid-stimulating hormone (TSH) receptor by thyrotropin receptor antibodies (TRAb). GD is the most common cause of thyrotoxicosis in children and adolescents, accounting for 10-15% of all thyroid illness in children and adolescents. The treatment of GD in children and adolesce...

hrp0086p1-p472 | Fat Metabolism and Obesity P1 | ESPE2016

Risk factors for Atherosclerosis after Anticancer Treatment in Childhood: The Assessment of Lipid Parameters and Indicators of Susceptibility to Atherosclerosis in a Group of Pediatric Patients after Anticancer Treatment

Połubok Joanna , Jasielska Olimpia , Gonera Aleksandra , Kozicka Marta , Sęga-Pondel Dorota , Kazanowska Bernarda , Barg Barg

Introduction: Lipid disorders are a common complication of anticancer therapy. These disorders may be included in both the metabolic syndrome or also may be associated with increased risk of cardiovascular disease. The aim of our study is to evaluate lipid profile in children after anticancer treatment.Materials and methods: Study group consisted of 44 patients (aged 3.25–16 years) with solid tumors, at least one year after cessation of anticancer t...

hrp0095p1-137 | Multisystem Endocrine Disorders | ESPE2022

First description of a child with a biallellic loss-of-function variant in the sulfate transporter SLC13A1

JJ Finken Martijn , Bokenkamp Arend , EC Smith Desiree , MC Wamelink Mirjam , EW Jansen Erwin , A Struijs Eduard , Waisfisz Quinten , Verkleij Marieke , F Hartmann Michaela , Wang Rong , A Wudy Stefan , Paganini Chiara , Rossi Antonio , M van de Kamp Jiddeke

Introduction: Sulfation is required for the metabolism of numerous compounds, including proteoglycans, steroid hormones, neurotransmitters, toxic chemicals, and drugs like acetaminophen. The sulfate transporter SLC13A1 is responsible for the intestinal absorption and the renal reabsorption of inorganic sulfate, but loss-of-function mutations in this gene have never been described in man. Here, we describe a male with a biallelic loss-of-function variant, i.e.,...

hrp0086p1-p31 | Adrenal P1 | ESPE2016

Growth of Children with Congenital Adrenal Hyperplasia (CAH) During the First 2 years of Life – Data from the Duth Longitudinal Registry

Linde Annelieke van der , Roeleveld Nel , vd Akker Erika , van Albada Mirjam , Hannema Sabine , Hoorweg-Nijman Gea , vd Kamp Hetty , Finken Martijn , Odink Roelof , van Trotsenburg Paul , Verkerk Paul , Claahsen Hedi

Background: A national database has been developed to register longitudinal data from all CAH children detected through neonatal screening from 2002 onwards. So far, data from 105 children have been registered (65% of Dutch CAH patients) to evaluate treatment and long-term effects in CAH.Aims: To evaluate height and weight in relation to medication used in the first 2 years of life.Methods: Biometric data and medication dosage were...

hrp0084p2-197 | Adrenals | ESPE2015

Evaluation of Medical Treatment in the First 2 Years of Life with a New Dutch National Longitudinal Registry for Children with Congenital Adrenal Hyperplasia (CAH)

van der Linde Annelieke , van den Akker Erica , Bakker- van Waarde Willy , Hannema Sabine , Hoorweg-Nijman Gea , van de Kamp Hetty , Klink Daniel , Odink Roelof , Straetemans Saartje , van Trotsenburg Paul , Verkerk Paul , Claahsen-van der Grinten Hedi

Background: Recently, a national database has been developed to register yearly data from all children detected with CAH in the neonatal screening program from 2002 onwards. So far longitudinal data of 105 children have been registered (roughly 65% of Dutch CAH patients) to evaluate medical treatment and long-term effects in CAH. A national CAH work group developed guidelines for diagnostics and follow up in CAH.Objective and hypotheses: Aim of our curre...